June 2020
Volume 61, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2020
Stereopure oligonucleotides achieve allele-selective reduction of P23H mutant rhodopsin
Author Affiliations & Notes
  • Vinod Vathipadiekal
    Biology, Wave Life Sciences, Cambridge, Massachusetts, United States
  • Lankai Guo
    Biology, Wave Life Sciences, Cambridge, Massachusetts, United States
  • Yuan Yin
    Biology, Wave Life Sciences, Cambridge, Massachusetts, United States
  • Qiong Shen
    Biology, Wave Life Sciences, Cambridge, Massachusetts, United States
  • Hailin Yang
    Biology, Wave Life Sciences, Cambridge, Massachusetts, United States
  • Richard Looby
    Biology, Wave Life Sciences, Cambridge, Massachusetts, United States
  • Lauren Norwood
    Biology, Wave Life Sciences, Cambridge, Massachusetts, United States
  • James Fransen
    Departments of Ophthalmology & Visual Sciences AND Anatomical Sciences and Neurobiology, University of Louisville, Kentucky, United States
  • archana jalligampala
    Departments of Ophthalmology & Visual Sciences AND Anatomical Sciences and Neurobiology, University of Louisville, Kentucky, United States
  • Jennifer Noel
    Departments of Ophthalmology & Visual Sciences AND Anatomical Sciences and Neurobiology, University of Louisville, Kentucky, United States
  • Chandra Vargeese
    Biology, Wave Life Sciences, Cambridge, Massachusetts, United States
  • Maureen A McCall
    Departments of Ophthalmology & Visual Sciences AND Anatomical Sciences and Neurobiology, University of Louisville, Kentucky, United States
  • Michael Byrne
    Biology, Wave Life Sciences, Cambridge, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Vinod Vathipadiekal, Wave Life Sciences (E); Lankai Guo, Wave Life Sciences (E); Yuan Yin, Wave Life Sciences (E); Qiong Shen, Wave Life Sciences (E); Hailin Yang, Wave Life Sciences (E); Richard Looby, Wave Life Sciences (E); Lauren Norwood, Wave Life Sciences (E); James Fransen, Wave Life Sciences (F); archana jalligampala, Wave Life Sciences (F); Jennifer Noel, Wave Life Sciences (F); Chandra Vargeese, Wave Life Sciences (E); Maureen McCall, Wave Life Sciences (F); Michael Byrne, Wave Life Sciences (E)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 1912. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Vinod Vathipadiekal, Lankai Guo, Yuan Yin, Qiong Shen, Hailin Yang, Richard Looby, Lauren Norwood, James Fransen, archana jalligampala, Jennifer Noel, Chandra Vargeese, Maureen A McCall, Michael Byrne; Stereopure oligonucleotides achieve allele-selective reduction of P23H mutant rhodopsin. Invest. Ophthalmol. Vis. Sci. 2020;61(7):1912.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : PRISMTM is Wave Life Sciences’ proprietary discovery and drug development platform that enables us to generate stereopure oligonucleotides targeting genetically defined diseases. PRISM combines our unique ability to construct stereopure oligonucleotides with a growing knowledge of how the interplay among oligonucleotide sequence, chemistry and backbone stereochemistry impacts key pharmacologic properties. Here, we report the application of PRISM to generate a stereopure oligonucleotide that promotes RNase H-mediated allele-selective degradation of mutant rhodopsin (RHO) transcripts, which encode a toxic gain-of-function protein (RHO P23H) and causes autosomal dominant retinitis pigmentosa (adRP).

Methods : Stereopure oligonucleotides were generated using PRISM. For all experiments, RNA levels were quantified by qPCR. We evaluated allele-selective activity against RHO alleles with a luciferase reporter assay in Cos7 cells. Potencies for stereopure oligonucleotides targeting RHOP23H were also evaluated in vitro in human retinal pigment epithelial (ARPE-19) cells overexpressing RHO. To assess target engagement, we quantified MALAT1, a proof of concept RNA, or RHOP23H transcripts in cellular and animal models. Animals received stereopure oligonucleotides or PBS as bilateral intravitreal (IVT) injections.

Results : Using MALAT1, we demonstrate that a single IVT injection of stereopure oligonucleotide leads to 50% knockdown in the posterior mouse eye for 9 months and >90% knockdown in the non-human primate (NHP) retina for at least 4 months. We also demonstrate that our stereopure oligonucleotide targeting RHO yields allele-selective degradation of RHOP23H RNA in biochemical and cellular experiments. Finally, we demonstrate target engagement in animal models of RHO P23H-induced adRP.

Conclusions : These results demonstrate that stereopure oligonucleotides induce potent and durable knockdown of MALAT1 in the mouse and NHP eye. We also show that stereopure oligonucleotides can achieve allele-selective knockdown of RHOP23H, suggesting that they may provide a viable therapeutic opportunity for addressing RHO P23H-dependent adRP.

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×